The MHRA Authorised Two Obesity Drugs in Two Days. Neither Is on the NHS.
Two MHRA authorisations in two days. One drug is too common to fund, the other too rare to prioritise. Neither is on the NHS.
Novo Nordisk
Scholar Rock Filed With Two Fill-Finish Sites. One Just Failed, and the Date Held.
Catalent Indiana failed its FDA inspection. Scholar Rock had named a second fill-finish site in the same BLA, so the PDUFA date did not move.
Brazil Approved Five Semaglutides in a Day. Sandoz Announced One of Them.
ANVISA approved five semaglutide products in a single day, including the one Sandoz will sell. Ozempic’s Brazilian patent expired in March.
Britain Thought It Had an Opt-Out. Washington Reads the Deal Differently.
Britain believed it had secured an exemption from the MFN reference basket. Washington reads the arrangement differently, and implementation is still being negotiated.
Novo Is Suing Lilly Over a Head-to-Head Trial Lilly Won, Arguing the Result Went Stale
Novo Nordisk filed a Lanham Act suit over Lilly’s Zepbound ads, arguing a genuine head-to-head result became misleading once a higher Wegovy dose launched.
Novo Nordisk Cuts Wegovy and Ozempic Self-Pay Price to $199 in New Access Push
Novo Nordisk has introduced a $199 introductory price for Wegovy and Ozempic starter doses, alongside a permanent drop in monthly self-pay costs to $349.
Pfizer wins $10 billion bidding war for Metsera after competitive bidding with Novo Nordisk
Months of legal challenges, court rulings, and regulatory probes define the industry’s fiercest metabolic takeover fight Pfizer has signed a definitive agreement to acquire metabolic biotech Metsera, ending months of one of the most aggressive takeover battles in recent biopharma history. The deal concludes a dramatic contest with Novo Nordisk, which had initially secured Metsera’s … Read more
Dutch Healthcare Institute Limits Early Access to Obesity Drugs Amid Cost and Evidence Concerns
The Dutch Healthcare Institute is taking a cautious, phased approach to new obesity drugs, limiting access to patients with the highest disease burden. The move reflects concerns about evidence gaps, cost-effectiveness, and the growing pressure obesity treatments could place on the national healthcare budget.
Takeover Battle: Novo Nordisk Wins Brave Court Victory in $10B Metsera Deal Amid FTC Probe
Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.
Obesity Drug Talks Reach Defining Moment as Lilly and Novo Near Trump Administration Pricing Deal
In a major policy moment, Lilly and Novo Nordisk are in active talks with U.S. officials to cap obesity drug prices, aligning political pressure with market strategy.